Detailed Narrative
Strong H2 FY26 Performance and Full-Year Growth
Influx Healthtech reported robust financial results for H2 FY26, with revenue from operations growing 41% year-on-year to INR80.1 crores, bringing the full-year FY26 revenue to INR146 crores. Profitability also saw significant improvement, with H2 FY26 PAT increasing 38% year-on-year to INR10.5 crores, and full-year PAT reaching INR20.5 crores. The full-year EBITDA margin expanded by 72 basis points to 20.3%, reflecting operational efficiency.
Major Capacity Expansion and Strategic Reallocation
The company is undertaking a significant capacity expansion with a new 75,000 square feet nutraceutical CDMO facility, expected to be operational by July or August 2026, which will increase overall installed capacity by 2.5 times. INR13.84 crores of IPO proceeds have been utilized for capex, and INR10 crores were strategically reallocated from other divisions to enhance the construction of this key nutraceutical facility. This reallocation aims to capitalize on strong demand in the nutraceutical segment.
Diversified Segment Growth and New Ventures
Nutraceuticals remained the largest segment, contributing INR131 crores with 40.3% YoY growth in FY26. Ayurvedic products showed the highest growth at 88.9% YoY, reaching INR6.1 crores, while cosmetics grew 15.8% to INR7.4 crores. In a new strategic move, Influx incorporated Olahey Wellness Private Limited with a INR1 lakh investment to manufacture ready-to-drink wellness beverages, aiming for brand diversification and international market opportunities.
Operational Efficiency and Client Relationships
Influx demonstrated improved operational efficiency, with its cash conversion cycle reducing significantly from 113 days in FY25 to 64 days in FY26. Debtor days improved to 84 days, and inventory days to 99 days. The company maintains a strong client base of over 718 clients with a 98% retention rate, highlighting strong long-term relationships and consistent product quality.
Future Outlook and International Expansion
Management provided a positive outlook, targeting a minimum revenue growth of 25-30% for FY27, with PAT margins maintained at approximately 14% and EBITDA margins at 20-22%. The new facility is projected to contribute INR40-50 crores in H2 FY27 and achieve a peak revenue of INR450-500 crores by FY29. International expansion is a key focus, with regulatory approvals secured in Tanzania and Nigeria, and an annual export growth target of 5-7% from the current 10-15%.
Gross Margin Dynamics and Employee Costs
Gross margins experienced a decline from 44% in H1 to 39% in H2 FY26, primarily due to a product mix skewed towards top clients and a lag in passing on increased raw material and packaging costs. Employee costs rose by 31% in H2 FY26, and 34% for the full year to INR11.8 crores, attributed to proactive hiring and training for the upcoming new facilities. Management expressed confidence in gross margin recovery in coming quarters.